tradingkey.logo
tradingkey.logo
Buscar

Apyx Medical Corp

APYX
Añadir a la lista de seguimiento
4.300USD
-0.360-7.73%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
180.03MCap. mercado
PérdidaP/E TTM

Más Datos de Apyx Medical Corp Compañía

Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment's product portfolio consists of Helium Plasma Technology, which is marketed and sold as Renuvion in the cosmetic surgery market, and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment produces generators, medical devices, and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It specializes in the design, development, and manufacturing of electrosurgical equipment and medical devices.

Información de Apyx Medical Corp

Símbolo de cotizaciónAPYX
Nombre de la empresaApyx Medical Corp
Fecha de salida a bolsaJul 22, 1983
Director ejecutivoGoodwin (Charles D)
Número de empleados220
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 22
Dirección5115 Ulmerton Rd
CiudadCLEARWATER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33760-4004
Teléfono18005372790
Sitio Webhttps://apyxmedical.com/
Símbolo de cotizaciónAPYX
Fecha de salida a bolsaJul 22, 1983
Director ejecutivoGoodwin (Charles D)

Ejecutivos de Apyx Medical Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
1.90M
+7.91%
Mr. Moshe Citronowicz
Mr. Moshe Citronowicz
Senior Vice President
Senior Vice President
493.50K
--
Mr. Lawrence J. (Larry) Waldman, CPA
Mr. Lawrence J. (Larry) Waldman, CPA
Lead Independent Director
Lead Independent Director
42.90K
--
Mr. Shawn David Roman
Mr. Shawn David Roman
Chief Operating Officer
Chief Operating Officer
16.47K
+27.13%
Mr. Matthew C. (Matt) Hill
Mr. Matthew C. (Matt) Hill
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
8.50K
--
Mr. Charles D. Goodwin, II
Mr. Charles D. Goodwin, II
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Wendy Levine
Ms. Wendy Levine
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
1.90M
+7.91%
Mr. Moshe Citronowicz
Mr. Moshe Citronowicz
Senior Vice President
Senior Vice President
493.50K
--
Mr. Lawrence J. (Larry) Waldman, CPA
Mr. Lawrence J. (Larry) Waldman, CPA
Lead Independent Director
Lead Independent Director
42.90K
--
Mr. Shawn David Roman
Mr. Shawn David Roman
Chief Operating Officer
Chief Operating Officer
16.47K
+27.13%
Mr. Matthew C. (Matt) Hill
Mr. Matthew C. (Matt) Hill
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
8.50K
--
Mr. Charles D. Goodwin, II
Mr. Charles D. Goodwin, II
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Apyx Medical Corp?

Los cinco principales accionistas de Apyx Medical Corp son: Mr. Stavros G. Vizirgianakis

¿Cuántas instituciones poseen acciones de Apyx Medical Corp (APYX)?

A fecha de 2026Q1, 105 instituciones poseen acciones de Apyx Medical Corp, con un valor de mercado combinado de aproximadamente 19.57M, lo que representa el 46.73% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1346948.00.